Header Logo

Connection

JOHN KIRKWOOD to Neoplasms

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Neoplasms.
JOHN KIRKWOOD
Connection Strength
1.734
Neoplasms
  1. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):632-46.
    View in: PubMed
    Score: 0.191
  2. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012 Sep-Oct; 62(5):309-35.
    View in: PubMed
    Score: 0.144
  3. Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treat Rev. 2013 Feb; 39(1):27-43.
    View in: PubMed
    Score: 0.143
  4. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer. 2011 Sep 06; 105(6):773-7.
    View in: PubMed
    Score: 0.136
  5. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther. 2008 Oct; 8(10):1583-93.
    View in: PubMed
    Score: 0.112
  6. Integrins and cancer. Oncology (Williston Park). 2007 Aug; 21(9 Suppl 3):13-20.
    View in: PubMed
    Score: 0.103
  7. Interferons in the treatment of solid tumors. Cancer Treat Res. 2005; 126:207-41.
    View in: PubMed
    Score: 0.086
  8. Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Cancer Res Commun. 2023 12 19; 3(12):2572-2584.
    View in: PubMed
    Score: 0.080
  9. Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2019 01 01; 37(1):72-80.
    View in: PubMed
    Score: 0.056
  10. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
    View in: PubMed
    Score: 0.056
  11. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018 05 14; 6(1):35.
    View in: PubMed
    Score: 0.055
  12. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther. 2018 02 01; 19(2):132-137.
    View in: PubMed
    Score: 0.053
  13. Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients. J Immunother. 1997 Sep; 20(5):387-98.
    View in: PubMed
    Score: 0.052
  14. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017; 5:44.
    View in: PubMed
    Score: 0.051
  15. Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann Surg Oncol. 1995 Jul; 2(4):365-71.
    View in: PubMed
    Score: 0.045
  16. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30; 5(24):12472-508.
    View in: PubMed
    Score: 0.043
  17. Interferons in the therapy of solid tumors. Oncology. 1994 Mar-Apr; 51(2):129-36.
    View in: PubMed
    Score: 0.041
  18. Interferon alpha in combination with other biologics: the scientific rationale. Br J Haematol. 1991 Oct; 79 Suppl 1:78-80.
    View in: PubMed
    Score: 0.034
  19. Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factor. J Immunother (1991). 1991 Apr; 10(2):84-95.
    View in: PubMed
    Score: 0.033
  20. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med. 2009 Jun 17; 7:45.
    View in: PubMed
    Score: 0.029
  21. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res. 2008 Jun 01; 14(11):3462-9.
    View in: PubMed
    Score: 0.027
  22. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 1985 Jul; 103(1):32-6.
    View in: PubMed
    Score: 0.022
  23. Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr; 2(4):336-52.
    View in: PubMed
    Score: 0.021
  24. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med. 1984 Apr; 76(4):593-6.
    View in: PubMed
    Score: 0.021
  25. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 2004 Mar; 50(3):564-73.
    View in: PubMed
    Score: 0.020
  26. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials. J Biol Response Mod. 1983; 2(6):540-7.
    View in: PubMed
    Score: 0.019
  27. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002 Apr; 13(2):119-34.
    View in: PubMed
    Score: 0.018
  28. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002 Mar-Apr; 25(2):97-138.
    View in: PubMed
    Score: 0.018
  29. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther. 2000 Dec; 6(4):171-6.
    View in: PubMed
    Score: 0.016
  30. A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med. 2008 Dec 23; 6:81.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.